67,545 Shares in Grifols, S.A. (NASDAQ:GRFS) Acquired by Crestline Management LP

Crestline Management LP acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 67,545 shares of the biotechnology company's stock, valued at approximately $503,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after buying an additional 1,527 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Grifols by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock worth $247,000 after purchasing an additional 1,657 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Grifols by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock worth $192,000 after purchasing an additional 2,403 shares during the period. R Squared Ltd purchased a new stake in Grifols during the 4th quarter worth about $28,000. Finally, HighTower Advisors LLC increased its holdings in Grifols by 28.3% during the 4th quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock worth $133,000 after purchasing an additional 3,936 shares during the period.

Analyst Upgrades and Downgrades

GRFS has been the topic of several recent research reports. StockNews.com upgraded Grifols from a "hold" rating to a "buy" rating in a report on Thursday. Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They set an "overweight" rating on the stock.

Grifols Stock Down 1.1%

Shares of GRFS traded down $0.09 during mid-day trading on Friday, reaching $7.76. The company's stock had a trading volume of 654,407 shares, compared to its average volume of 1,169,715. Grifols, S.A. has a 12-month low of $5.79 and a 12-month high of $9.96. The stock has a market cap of $5.34 billion, a PE ratio of 6.66 and a beta of 0.44. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The company's 50 day moving average is $7.29 and its 200 day moving average is $7.64.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.